Skip to main content
ERYTECH Pharma S.A. logo

ERYTECH Pharma S.A. — Investor Relations & Filings

Ticker · ERYP ISIN · FR001400K4B1 LEI · 969500U8ZZCODU8A9374 PA Manufacturing
Open in API
Filings indexed 864 across all filing types
Latest filing 2023-09-19 Regulatory Filings
Country FR France
Listing PA ERYP

About ERYTECH Pharma S.A.

https://phaxiam.com/

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Recent filings

Filing Released Lang Actions
PHAXIAM Therapeutics étend son portefeuille de phages à une nouvelle cible bactérienne résistante et agressive, Klebsiella pneumoniae
Regulatory Filings Classification · 1% confidence The document is a press release dated September 19, 2023, announcing a new preclinical development program targeting the resistant bacterium *Klebsiella pneumoniae*. It details scientific rationale, market context (incidence and resistance rates), and quotes the CEO regarding strategy. This type of announcement, focusing on a specific scientific or business development update rather than comprehensive financial results (10-K, IR) or a formal shareholder vote/meeting material (AGM-R, DEF 14A), fits best under the general category of corporate news or regulatory updates. Since it is an announcement of a strategic development (new target/program) and not a formal financial report, it is classified as a Regulatory Filing (RNS) as a broad category for corporate news that doesn't fit the more specific financial or governance codes. It is too detailed for a simple Earnings Release (ER) and is not a transcript (CT) or a presentation (IP). Given the context of a biotech company announcing a pipeline update, RNS is the most appropriate general regulatory filing category.
2023-09-19 French
PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target
Regulatory Filings Classification · 1% confidence The document is a press release dated September 19, 2023, announcing a strategic development: PHAXIAM Therapeutics is extending its phage portfolio to target *Klebsiella pneumoniae*. It details the medical need, the company's plans for preclinical development, and includes quotes from the CEO. This type of announcement, focusing on R&D pipeline progress and strategic updates rather than formal financial results (like 10-K or ER) or management changes (MANG), best fits the category for updates on financing, capital structure, or significant corporate activities that aren't covered by other specific codes. Since it announces a new development program and aligns with the company's strategy, it is most closely related to corporate/financing updates or general news. Given the options, it is a significant corporate announcement. It is not a formal regulatory filing like 10-K, an earnings release (ER), or a management discussion (MDA). It is a general corporate announcement about pipeline expansion. Since there isn't a specific 'Pipeline Update' code, and it's not a formal financial report, it falls under general corporate news. The closest fit among the provided codes for a significant, non-financial, non-management-change corporate announcement is often a general regulatory filing (RNS) or potentially a Capital/Financing Update (CAP) if the development implies future funding needs, but here it's purely operational/R&D news. However, looking closely at the definitions, this is a standard press release announcing a business development/pipeline expansion. In many classification schemes, these fall under 'Regulatory Filings' (RNS) if they are mandatory disclosures, or sometimes a general 'Investor Relations' category. Given the provided list, RNS is the most appropriate fallback for a significant, non-financial, non-meeting-related press release that doesn't fit elsewhere. It is not a DEF 14A (Remuneration), DIRS (Insider Trading), or DIV (Dividend). It is a general corporate update.
2023-09-19 English
PHAXIAM Therapeutics annonce la finalisation des opérations de regroupement de ses actions
Share Issue/Capital Change Classification · 1% confidence The document explicitly announces the finalization of a share consolidation operation ('regroupement d'actions'). This involves exchanging old shares for new shares (10 old for 1 new) and details the effective date (September 18, 2023) and the resulting number of shares. This action directly relates to changes in the company's capital structure and financing terms. Based on the definitions, the most appropriate category is 'Capital/Financing Update' (CAP), as it details a structural change to the equity capital.
2023-09-18 French
PHAXIAM Therapeutics announces the completion of its reverse share split
Share Issue/Capital Change Classification · 1% confidence The document explicitly announces the 'completion of its reverse share split' and details the exchange ratio (ten existing shares for one new share), the effective date (September 18th, 2023), and the resulting number of shares. This action directly relates to a change in the company's capital structure. Based on the provided definitions, the 'Share Issue/Capital Change' (SHA) category is the most appropriate fit for a reverse share split announcement, as it is a fundamental change to the capital structure. It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), but a specific corporate action regarding shares.
2023-09-18 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 août 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 août 2023" and explicitly references Article 223-16 of the AMF General Regulation (Autorité des Marchés Financiers). It presents a table showing the evolution of the total number of shares and voting rights over several months, culminating in the August 31, 2023 figure. This type of mandatory monthly disclosure regarding the total share capital and voting rights structure is a specific regulatory filing requirement in France, often related to major shareholding notifications or capital structure transparency. While it touches upon share capital changes, its primary function is the regular reporting of voting rights and share count. This aligns best with the 'Major Shareholding Notification' (MRQ) category, as these reports are often triggered by or coincide with changes in the capital structure that affect ownership thresholds, or are required monthly regardless of threshold breaches to maintain transparency on the total voting base. Given the specific focus on 'droits de vote' (voting rights) and 'capital social' (share capital) reported monthly, MRQ is the most appropriate fit among the provided options, as it deals with the underlying structure that dictates major holdings.
2023-09-08 French
Monthly information related to total number of voting rights and shares composing the share capital _August 31, 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Monthly information related to total number of voting rights and shares composing the share capital" for August 31, 2023, and references Article 223-16 of the French AMF regulation. It provides a table detailing the evolution of the total number of shares and voting rights over several months. This type of regular disclosure concerning the total share capital and voting rights is a specific regulatory requirement, often related to transparency regarding ownership structure or potential takeover thresholds. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). It most closely aligns with a regulatory disclosure regarding share capital structure, which fits best under the general 'Regulatory Filings' (RNS) category, as there is no specific code for 'Monthly Voting Rights Disclosure'. Given the nature of the data (share capital and voting rights), it is a mandatory regulatory filing.
2023-09-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.